Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL
NCT06111625
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Leukemia, Lymphoid
Interventions
DRUG:
blinatumomab
Sponsor
Sichuan University